Impaired response to therapy and drug resistance were frequently observed in RAS-MAPK mutated CLL; in particular, KRAS mutations were associated with worse overall response to lenalidomide-based therapy [28], and with no response to chlorambucil/CD20-antibody chemoimmunotherapy [27]. Here, KRAS is linked to B-cell chronic lymphocytic leukemia.